logo
Digital Tool Improves Early Dementia Detection

Digital Tool Improves Early Dementia Detection

Medscape19-05-2025

CHICAGO — Combining machine learning and patient-reported tools significantly improved early detection of dementia in primary care, according to new research presented at the annual meeting of the American Geriatrics Society (AGS) 2025 Annual Scientific Meeting.
Researchers from Indiana University Indianapolis found that using a machine learning algorithm and a patient-reported screening tool — together known as the Digital Detection of Dementia (D3) approach — led to a 44% higher likelihood of a clinician diagnosing a patient with dementia over a 1-year period compared with usual care.
The researchers tested the D3 model in a randomized trial across nine federally qualified health centers (FQHCs) in Indianapolis.
Of the more than 5300 patients aged 65 years or older who enrolled, 62% were women, and more than half were Black or Hispanic.
The clinics were assigned to provide three types of care, the first being usual care.
Patients in the second group were evaluated for dementia using the passive digital marker, an artificial intelligence (AI) algorithm that analyzed existing electronic health record data to flag potential cases.
Clinicians at the third clinic evaluated patients by analyzing results from the Quick Dementia Rating System, a 10-item questionnaire that takes patients 2-3 minutes to complete, and viewed flagged cases produced by the algorithm.
Providers at the third clinic diagnosed significantly more patients with dementia than those at clinics using usual care, even after accounting for age, sex, race, and ethnicity (odds ratio, 1.44; 95% CI, 1.19-1.75).
In contrast, clinics using only the AI tool showed no statistically significant increase in diagnoses. Researchers hypothesized that even partial use of the questionnaire — completed by just 21% of eligible patients — may have improved clinicians' trust in AI alerts, nudging them toward making a diagnosis.
'Providers…are very busy and are bombarded with computerized decision support,' said lead study researcher Malaz Boustani, MD, a geriatrician and professor of aging research at Indiana University. But 'with the right messenger and time,' trust in digital tools can grow and lead to behavior change.
According to previous research, 62% of older adults seen in FQHCs have mild cognitive impairment, and 12% have dementia. Yet most go undiagnosed. Black patients were more than twice as likely as White patients to have unrecognized cognitive decline.
The tools were embedded directly into the clinics' electronic health record system, triggering alerts in the chart view. Patients were offered the questionnaire during electronic check-in. A clinical decision support system then guided clinicians with next steps.
'This hybrid model lets clinicians do the right thing without adding to their workload,' Boustani said.
The D3 model is now being evaluated for broader implementation, Boustani said. He and his colleagues are also exploring ways to increase patient completion of the questionnaire and refine clinician prompts.
'We're waiting on the result of an ongoing trial that is trying to replicate our study using interruptive alerts instead of non-interruptive alerts,' Boustani said. 'If that trial shows similar or better results, we will work with existing consulting companies to distribute the digital tools across the country.'
Boustani serves as a chief scientific officer and co-founder of two private companies and has various financial relationships involving equity with other companies. He also serves on various advisory boards for pharmaceutical companies.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Which Class of ER Degrader Is Better?
Which Class of ER Degrader Is Better?

Medscape

time14 minutes ago

  • Medscape

Which Class of ER Degrader Is Better?

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), outshone the commonly used selective estrogen receptor degrader (SERD) fulvestrant in a phase 3 trial of second-line treatment for a subset of patients with breast cancer. The VERITAC-2 trial included patients with ER-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-), locally advanced or metastatic disease who had failed prior treatment with cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and endocrine therapy, and no exposure to chemotherapy in the advanced setting. Only a subset of the study cohort, those with estrogen receptor 1-mutant disease, experienced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when treated with vepdegestrant compared with patients treated with fulvestrant. 'These results support vepdegestrant as a potential monotherapy treatment option for patients with previously treated ESR1 -mutant ER+/HER2- advanced breast cancer,' said lead author Erika P. Hamilton, MD, a medical oncologist and director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, Nashville, Tennessee, during a press conference for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings were simultaneously published in the New England Journal of Medicine . Vepdegestrant is not approved by the US Food and Drug Administration, but received fast-track status in February 2024 as monotherapy for this patient population. It is the first and only PROTAC ER degrader to be evaluated in a phase 3 clinical trial in breast cancer. PROTACs represent a novel class of therapeutic agents that harness the proteasome to selectively degrade target proteins. 'There's no established consensus for patients getting treatment in the second-line setting after progression on endocrine therapy and a CDK 4/6 inhibitor,' explained Hamilton. 'One of the mainstays of our treatment really has been fulvestrant, which clearly has some challenges. First, it's administered intramuscularly, and second, in a post-CDK 4/6 landscape, we know that progression-free survival is very short — on the order of less than 2 months.' Besides fulvestrant, the oral SERD elacestrant was FDA-approved in January 2023, and other oral SERDs are in development, she noted. Trial Design The new trial included 624 patients with advanced ER+/HER2- disease that had progressed following one or two lines of endocrine therapy and a CDK 4/6 inhibitor. 'They could not have received fulvestrant already or chemotherapy, and patients had to have benefited from their previous line of endocrine therapy for at least 6 months to enter the study,' Hamilton noted. Study participants were also stratified by the presence or absence of visceral disease, as well as the presence of an ESR1 mutation (n = 270). Such mutations are a common cause of acquired resistance found in approximately 40% of patients in the second-line setting, according to a press release from the drug developer. Patients were randomly assigned 1:1 to 28-day treatment cycles of either 200 mg oral vepdegestrant once daily, or 500 mg intramuscular fulvestrant on day 1 and day 15 of the first cycle, and then on day 1 of each subsequent cycle. The primary endpoint was PFS by blinded, independent central review, first in patients with ESR1 mutations and then in the entire cohort. Key secondary endpoints were overall survival, objective response rate, and clinical benefit rate, which was defined as the rate of confirmed clinical or partial response at any time, or stable disease, nonclinical response, or nonprogressive disease for at least 24 weeks. Vepdegestrant vs Fulvestrant The study met its key primary endpoint, showing a median PFS of 5.0 months with vepdegestrant compared with 2.1 months with fulvestrant (hazard ratio [HR] 0.57; P < .001) in the 270 patients with ESR1 mutations. At 6 months, twice as many patients in the vepdegestrant arm remained progression-free compared with those in the fulvestrant arm (45.2% vs 22.7%). However, this primary endpoint was not significantly different between groups when calculated for the entire patient population (HR, 0.83; P = .07). For the key secondary endpoints, among patients with ESR1 mutations, the clinical benefit rate was more than double in patients receiving vepdegestrant (42.1% vs 20.2%). Similarly, the objective response rate was more than four times higher (18.6% vs 4%) Commenting in a press release, ASCO breast cancer expert Jane Lowe Meisel, MD, said that although the trial found that vepdegestrant worked better than fulvestrant in patients with ESR1 mutations, 'on average, patients did not have prolonged responses on either agent, highlighting the need for combination therapies and continued development in this space.' Meisel is co-director of Breast Medical Oncology at the Winship Cancer Institute of Emory University School of Medicine in Atlanta, Georgia. 'Overall survival was very immature at the time of this analysis, with only 20% of the anticipated events occurring,' added lead investigator Hamilton. Treatment-emergent adverse events (TEAEs) led to discontinuation in 3% of patients taking vepdegestrant and 1% of patients taking fulvestrant. TEAEs leading to dose reductions occurred in 2% of the vepdegestrant group and none in the fulvestrant group. The three most common AEs of any grade were fatigue (27% in vepdegestrant group, 16% fulvestrant group) and increased aspartate aminotransferase and alanine aminotransferase levels of any grade (14% vepdegestrant group, 10% fulvestrant group). Oral SERDS vs Vepdegestrant Side Effects Compared to oral SERDs, vepdegestrant has a favorable side effect profile, Hamilton said. 'Oral SERDs have prominent GI side effects as their most frequent side effect.' But, across all grades, rates of both vomiting and diarrhea were only 6% with vepdegestrant. GI side effects tend to be more common, 'in the 30% or 40% range with oral SERDs,' she told Medscape Medical News . Study discussant William John Gradishar, MD, emphasized the importance of reducing side effects. ' Vepdegestrant now joins a growing list of drugs that perform better than current standard of care monotherapy' in the ESR1 -mutant population, he noted in the session. But the reality is that most of these drugs are being developed to be used in combination with targeted therapies, 'and increased toxicity can be expected with doublet therapy…Quality of life measures as experienced and reported by patients are critical, and even modest changes in symptom and functional domains should not be minimized,' said Gradishar, professor of breast oncology at Northwestern University Feinberg School of Medicine, Chicago, Illinois. 'Vepdegestrant has demonstrated compelling preclinical activity and encouraging early clinical data supporting its efficacy in degrading ER,' said Albert Grinshpun, MD, in an interview with Medscape Medical News . Grinshpun, head of the Breast Cancer Service at Shaare Zedek Medical Center and The Hebrew University, Jerusalem, Israel, said his initial takeaway from the study is that 'vepdegestrant now stands alongside other oral SERDs, such as elacestrant and imlunestrant, in demonstrating superiority over fulvestrant, specifically in the context of ESR1­ -mutant [disease].' 'Importantly, the treatment landscape for patients progressing on CDK 4/6 inhibitors is rapidly evolving, with a growing shift toward combination therapies rather than fulvestrant monotherapy,' he said. 'In my view, vepdegestrant has established itself as a promising endocrine backbone for future combination strategies. Its favorable toxicity profile makes it particularly well-suited for pairing with a range of targeted agents or even antibody-drug conjugates, including inhibitors of PIK3CA and KAT6 , in the pursuit of more effective therapeutic regimens.' The study was jointly funded by Arvinas Estrogen Receptor, Inc. and Pfizer. Hamilton disclosed consulting or advisory roles with Accutar Biotechnology (Inst), Arvinas (Inst), AstraZeneca (Inst), Circle Pharma (Inst), Daiichi Sankyo (Inst), Ellipses Pharma (Inst), Entos (Inst), Fosun Pharma (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), Janssen (Inst), Jazz Pharmaceuticals (Inst), Jefferies (Inst), Johnson & Johnson (Inst), Lilly (Inst), Medical Pharma Services (Inst), Mersana (Inst), Novartis (Inst), Olema Pharmaceuticals (Inst), Pfizer (Inst), Stemline Therapeutics (Inst), Tempus (Inst), Theratechnologies (Inst), Tubulis GmbH (Inst), Verascity Science (Inst), and Zentalis (Inst). Hamilton has also received research funding from AbbVie (Inst), Accutar Biotech (Inst), Acerta Pharma (Inst), ADC Therapeutics (Inst), Akeso Biopharma (Inst), Amgen (Inst), Aravive (Inst), ArQule (Inst), Artios (Inst), Arvinas (Inst), AstraZeneca (Inst), AtlasMedx (Inst), BeiGene (Inst), Black Diamond Therapeutics (Inst), Bliss Biopharmaceutical (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Cascadian Therapeutics (Inst), Clovis Oncology (Inst), Compugen (Inst), Context Therapeutics (Inst), Cullinan Oncology (Inst), Curis (Inst), CytomX Therapeutics (Inst), Daiichi Sankyo (Inst), Dana-Farber Cancer Institute (Inst), Dantari (Inst), Deciphera (Inst), Duality Biologics (Inst), eFFECTOR Therapeutics (Inst), Eisai (Inst), Ellipses Pharma (Inst), Elucida Oncology (Inst), EMD Serono (Inst), Fochon Pharmaceuticals (Inst), Fujifilm (Inst), G1 Therapeutics (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), H3 Biomedicine (Inst), Harpoon (Inst), Hutchison MediPharma (Inst), Immunogen (Inst), Immunomedics (Inst), Incyte (Inst), Infinity Pharmaceuticals (Inst), Inspirna (Inst), InventisBio (Inst), Jacobio (Inst), K-Group Beta (Inst), Karyopharm Therapeutics (Inst), Kind Pharmaceuticals (Inst), Leap Therapeutics (Inst), Lilly (Inst), Loxo (Inst), Lycera (Inst), MabSpace Biosciences (Inst), Macrogenics (Inst), MedImmune (Inst), Mersana (Inst), Merus (Inst), Millennium (Inst), Molecular Templates (Inst), Myriad Genetics (Inst), Novartis (Inst), Nucana (Inst), Olema Pharmaceuticals (Inst), OncoMed (Inst), Oncothyreon (Inst), ORIC Pharmaceuticals (Inst), Orinove (Inst), Orum Therapeutics (Inst), Pfizer (Inst), PharmaMar (Inst), Pieris Pharmaceuticals (Inst), Pionyr (Inst), Plexxikon (Inst), Prelude Therapeutics (Inst), ProfoundBio (Inst), Radius Health (Inst), Regeneron (Inst), Relay Therapeutics (Inst), Repertoire Immune Medicines (Inst), Rgenix (Inst), Seagen (Inst), Sermonix Pharmaceuticals (Inst), Shattuck Labs (Inst), Silverback Therapeutics (Inst), Stem CentRx (Inst), Stemline Therapeutics (Inst), Sutro Biopharma (Inst), Syndax (Inst), Syros Pharmaceuticals (Inst), Taiho Pharmaceutical (Inst), TapImmune Inc. (Inst), Tesaro (Inst), Tolmar (Inst), Torque (Inst), Treadwell Therapeutics (Inst), Verastem (Inst), Zenith Epigenetics (Inst), and Zymeworks (Inst). Meisel disclosed consulting or advisory roles with AstraZeneca, GE Healthcare, Genentech, Novartis, Olema Oncology, Pfizer, SeaGen, Sermonix Pharmaceuticals, and Stemline, and research funding from AstraZeneca (Inst), Olema Oncology (Inst), Pfizer (Inst), Seagen (Inst), and Sermonix Pharmaceuticals (Inst). Grinshpun disclosed honoraria from GSK, Lilly, Novartis, and AstraZeneca, and travel from Roche, Pfizer, and AstraZeneca. Gradishar disclosed consulting or advisory roles with AstraZeneca , Genentech/Roche, Gilead Sciences, Merck, Novartis, Pfizer.

Derrick Lewis Says He Nearly Had To Beg To Get UFC Nashville Fight
Derrick Lewis Says He Nearly Had To Beg To Get UFC Nashville Fight

Forbes

time42 minutes ago

  • Forbes

Derrick Lewis Says He Nearly Had To Beg To Get UFC Nashville Fight

ST LOUIS, MISSOURI - MAY 11: (L-R) Derrick Lewis battles Rodrigo Nascimento of Brazil in a ... More heavyweight fight during the UFC Fight Night event at Enterprise Center on May 11, 2024 in St Louis, Missouri. (Photo by Josh Hedges/Zuffa LLC via Getty Images) Derrick Lewis, who holds the record for most knockout wins in UFC history, has his next fight booked. However, the former UFC heavyweight title challenger, who has not set foot inside the Octagon for more than a year, said securing the UFC Nashville main event fight opposite Tallison Teixeira was not easy. "It's crazy that nobody's fighting right now," Lewis recently told MMA Junkie. "Heavyweight, I don't know what's going on. I damn near had to beg to get this fight, so I don't know what's going on. Hopefully we can stay active after this." UFC Nashville takes place on July 12 at Bridgestone Arena in Nashville, Tennessee. Lewis (28-12-0-1) is the No. 9 fighter in the official UFC heavyweight rankings. The 40-year-old former UFC title challenger is coming off a May 2024 knockout win over Rodrigo Nascimento. Lewis, who owns the record for most knockouts in UFC history with 15, is 2-4 in his past six trips to the Octagon dating back to February 2022. Lewis has been with the UFC since 2014. He also has the UFC record for most finishes in the heavyweight division with 15. No active UFC heavyweight has as many fights in the Octagon as Lewis does at 29. Lewis has a UFC heavyweight record eight fight-night bonus awards. Lewis was scheduled to face Jhonata Diniz in November, but he was forced to withdraw from that contest after he had weighed in because of an undisclosed medical issue. Teixeira (8-0) joined the UFC in 2024 with a knockout win on a Dana White Contender Series card. The 25-year-old made his official UFC debut in February 2025, scoring a first-round knockout and a "Performance of the Night" bonus in a win over Justin Tafa. The UFC is wasting no time in throwing Teixeira into the deep end of the heavyweight pool, giving him a veteran opponent in a main event contest. All eight of Teixeira's career wins have come via first-round stoppage (seven knockouts, one submission). He has been a pro since 2021. He is ranked No. 14 in the UFC's heavyweight weight class. Lewis said of Teixeira, "I know he's Brazilian, and he's a tall guy. He's a heavyweight, so pretty sure he's got knockout power. I didn't watch any of his fights yet, nothing like that, but my coach told me he's got a lot of first-round knockouts. ... I've been training for like four months now, non-stop really, down to every day, and I never did that before. I'm coming into this fight, I'm pretty sure I'm going to be in great shape. My six pack will be back." "Yeah, I'm comfortable," Lewis added. "I like fighting tall guys. It aligns with my right hand. The way I throw my right hand, it aligns with it." We will have more information on Derrick Lewis vs. Tallison Teixeira and the UFC Nashville fight card as information becomes available. The UFC Fight Night card is airs on ESPN and ESPN+.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store